USA - NASDAQ:SNES - US81720R6045 - Common Stock
The current stock price of SNES is 3.195 USD. In the past month the price decreased by -20.25%. In the past year, price increased by 26.77%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 44.96 | 935.69B | ||
| JNJ | JOHNSON & JOHNSON | 18.67 | 466.81B | ||
| MRK | MERCK & CO. INC. | 10.32 | 227.17B | ||
| PFE | PFIZER INC | 7.97 | 145.04B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.43 | 99.17B | ||
| ZTS | ZOETIS INC | 18.95 | 53.23B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.48 | 22.72B | ||
| VTRS | VIATRIS INC | 4.81 | 13.06B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.81 | 11.36B | ||
| CORT | CORCEPT THERAPEUTICS INC | 89.78 | 8.33B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.97B | ||
| LGND | LIGAND PHARMACEUTICALS | 28.63 | 4.09B |
SenesTech, Inc. engages in the development and commercialization of proprietary technology for the management of animal pest populations. The company is headquartered in Phoenix, Arizona and currently employs 23 full-time employees. The company went IPO on 2016-12-08. The Company’s product lines of fertility control products are: ContraPest, Evolve Rat, and Evolve Mouse. Its product, ContraPest, is a liquid bait containing the active ingredients 4-vinylcyclohexene diepoxide (VCD) and triptolide. ContraPest targets the reproductive systems of both male and female Norway and roof rats beginning with the first breeding cycle following consumption, which can lead to sustained reductions in the rat population. The Evolve Rat is a soft bait product that contains the active ingredient, cottonseed oil, which reduces fertility in both male and female rats. The Evolve Mouse, a modified version of soft bait technology containing the active ingredient cottonseed oil, which limits reproduction of male and female mice after one to two breeding cycles following consumption.
SENESTECH INC
777 W. Pinnacle Peak Road, Suite B104
Phoenix ARIZONA 85027 US
CEO: Kenneth Siegel
Employees: 23
Phone: 19287794143
SenesTech, Inc. engages in the development and commercialization of proprietary technology for the management of animal pest populations. The company is headquartered in Phoenix, Arizona and currently employs 23 full-time employees. The company went IPO on 2016-12-08. The Company’s product lines of fertility control products are: ContraPest, Evolve Rat, and Evolve Mouse. Its product, ContraPest, is a liquid bait containing the active ingredients 4-vinylcyclohexene diepoxide (VCD) and triptolide. ContraPest targets the reproductive systems of both male and female Norway and roof rats beginning with the first breeding cycle following consumption, which can lead to sustained reductions in the rat population. The Evolve Rat is a soft bait product that contains the active ingredient, cottonseed oil, which reduces fertility in both male and female rats. The Evolve Mouse, a modified version of soft bait technology containing the active ingredient cottonseed oil, which limits reproduction of male and female mice after one to two breeding cycles following consumption.
The current stock price of SNES is 3.195 USD. The price decreased by -8.19% in the last trading session.
SNES does not pay a dividend.
SNES has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
The Revenue of SENESTECH INC (SNES) is expected to grow by 31.65% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
SENESTECH INC (SNES) currently has 23 employees.
SENESTECH INC (SNES) will report earnings on 2026-03-10, after the market close.
ChartMill assigns a fundamental rating of 3 / 10 to SNES. SNES has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months SNES reported a non-GAAP Earnings per Share(EPS) of -9.97. The EPS increased by 96.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -58.36% | ||
| ROE | -86.7% | ||
| Debt/Equity | 0.03 |
7 analysts have analysed SNES and the average price target is 10.2 USD. This implies a price increase of 219.25% is expected in the next year compared to the current price of 3.195.
For the next year, analysts expect an EPS growth of 71.05% and a revenue growth 31.65% for SNES